Primary bone lymphoma or non-Hodgkin lymphoma of bone is a rare disease. There are only a few case series of stage IE of this condition in medical literature. The aim of this study is to determine the rate of survival
for stage IE after combined modality treatment, the rate of local recurrence, and the results of limb salvage in cases
of local recurrence.
We collected data from 61 patients with histologically confirmed PBL treated at the Musculoskeletal
Oncology Department of our hospital from 2000 to 2010. Retrospective evaluation included demographics, symptoms, tumor locations, outcomes of surgical treatment for local recurrence and survival rates. Results:
All patients received Combined Modality Therapy. Overall,five year survival was 89% and five year disease free survival rate was 78%. Local recurrence occurred in 6 patients during follow up period, which was treated surgically
by wide excision and reconstruction. The mean follow-up for the local recurrence group was 36(24-54) months and mortality rate in this group was 17%. Conclusions:
Combined Modality Therapy for stage IE primary bone lymphomaresults in good survival rate. In case
of local recurrence, wide excision and reconstruction improves the outcomes.
Zinzani PL, Carrillo G, Ascani S, Barbieri E, Tani M, Paulli M, et al. Primary bone lymphoma: experience with 52 patients. Haematologica. 2003;88:280-5.
Fidias P, Spiro I, Sobczak ML, Nielsen GP, Ruffolo EF, Mankin H, et al. Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys. 1999; 45:1213-8.
Fairbanks RK, Bonner JA, Inwards CY, Strickler JG, Habermann TM, Unni KK, et al. Treatment of stage IE primary lymphoma of bone. Int J Radiat Oncol Biol Phys. 1994; 28:363-72.
Ramadan KM, Shenkier T, Sehn LH, Gascoyne RD, Connors JM. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: A population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol. 2007; 18: 129-35.
Deshmukh C, Bakshi A, Parikh P, Nair R, Pai V, Gupta S, et al. Primary non-Hodgkin’s lymphoma of the bone: a single institution experience. Med Oncol. 2004; 21:263-8.
Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer. 2006; 106: 2652-6.
Mirel H. Metastatic disease in long bones: a proposed scoring systems for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989; 249:256–64.
Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstruction procedures after surgical treatment of tumors of the musculoskeletal system.Clin Orthop Relat Res. 1993; 286:241-6.
Heyning FH, Hogendoorn PC, Kramer MH, Hermans J, Kluin-Nelemans JC, Noordijk EM, et al. Primary non- Hodgkin,s lymphoma of bone: a clinicopathologic investigation of 60 cases. Leukemia. 1999;13:2094-8.
Mulligan ME, McRae GA, Murphy MD. Imaging features of primary lymphoma of bone. Am J Roentgeno.199l; 173:1691-7.
Horsman JM, Thomas J, Hough R, Hancock BW. Primary bone lymphoma: a retrospective analysis. Int J Oncol. 2006; 28:1571-5.
Hicks DG, Gokan T, O’Keefe RJ, Totterman SM, Fultz PJ, Judkins AR, et al. Primary lymphoma of bone: Correlation of magnetic resonance imaging features with cytokine production by tumor cells. Cancer. 1995; 75:973-80.
Braunstein EM, White SJ. Non-Hodgkin lymphoma of bone. Radiology. 1980; 135:59-63.
Glotzbecker MP1, Kersun LS, Choi JK, Wills BP, Schaffer AA, Dormans JP. Primary non-Hodgkin’s lymphoma of bone in children. J Bone Joint Surg Am. 2006; 88: 583-94.
Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998; 339:21-6.
Barbieri E, Cammelli S, Mauro F, Perini F, Cazzola A, Neri S, et al. Primary non-Hodgkin’s lymphoma of the bone: treatment and analysis of prognostic factors for stage I and stage II. Int J Radiat Oncol Biol Phys. 2004; 59:760-4.
Kim SY, Shin DY, Lee SS, Suh C, Kwak JY, Kim HG, et al. Clinical characteristics and outcomes of primary bone lymphoma in Korea. Korean J Hematol. 2012; 47: 213-8.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-42.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005; 23: 4117-26.
Maruyama D, Watanabe T, Beppu Y, Kobayashi Y, Kim S, TanimotoK, et al. Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol. 2007; 37: 216–23.